6377-18-0CO[C@H]1[C@@H](O)[C@@H](C)O[C@H](O[C@H]2[C@H](Oc3cccc4c(O)c5c(=O)oc6ccc(C)c7c(=O)oc(c34)c5c67)O[C@H](C)[C@H](O)[C@@H]2O)[C@@H]1OPONPPNYZKHNPKZ-RYBWXQSLSA-NChartreusin is a glycoside and a benzochromenone.
Warning
H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 66 reports by companies from 2 notifications to the ECHA C&L Inventory.
UsesChartreusin is an antiproliferative agent that inhibits topoisomerase II.
UsesChartreusin is an antitumour antibiotic that binds to GC-rich tracts in DNA, with a clear preference for B-DNA over Z-DNA. It inhibits RNA synthesis and causes single-strand scission of DNA via the formation of free radicals. Chartreusin is also a potent inhibitor of topoisomerase II.
UsesChartreusin is an antitumor antibiotic that binds to GC-rich tracts in DNA, with a clear preference for B-DNA over Z-DNA. It inhibits RNA synthesis and causes single-strand scission of DNA via the formation of free radicals. Chartreusin is also a potent inhibitor of topoisomerase II.
Loading…
6377-18-0DTXSID20930431CHEMBL1554674CHEBI:3580DefinitionChEBI: Chartreusin is a glycoside and a benzochromenone.